Symbols / CVM
CVM Chart
About
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 40.77M |
| Enterprise Value | 39.63M | Income | -25.41M | Sales | — |
| Book/sh | 1.99 | Cash/sh | 1.30 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -5.27 | PEG | — |
| P/S | — | P/B | 2.44 | P/C | — |
| EV/EBITDA | -1.74 | EV/Sales | — | Quick Ratio | 2.14 |
| Current Ratio | 2.26 | Debt/Eq | 58.81 | LT Debt/Eq | — |
| EPS (ttm) | -6.27 | EPS next Y | -0.92 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-02-12 | ROA | -56.24% |
| ROE | -176.32% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 8.41M |
| Shs Float | 7.71M | Short Float | 6.26% | Short Ratio | 6.63 |
| Short Interest | — | 52W High | 20.40 | 52W Low | 1.98 |
| Beta | 0.82 | Avg Volume | 69.39K | Volume | 4.34K |
| Target Price | $42.50 | Recom | None | Prev Close | $4.90 |
| Price | $4.85 | Change | -1.04% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$42.50
Mean price target
2. Current target
$4.85
Latest analyst target
3. DCF / Fair value
$-17.53
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.85
Low
$25.00
High
$60.00
Mean
$42.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-07-12 | reit | EF Hutton | Buy → Buy | $10 |
| 2023-03-09 | reit | EF Hutton | — → Buy | $10 |
| 2022-12-29 | main | EF Hutton | — → Buy | $16 |
| 2022-04-07 | init | EF Hutton | — → Buy | $17 |
| 2020-01-13 | init | HC Wainwright & Co. | — → Buy | $18 |
| 2013-02-20 | init | Taglich Brothers | — → Speculative Buy | — |
| 2013-02-13 | init | Chardan Capital | — → Buy | $1 |
| 2013-01-14 | init | Laidlaw & Co. | — → Buy | $1 |
News
RSS: Latest CVM news- Cel-Sci Corporation (CVM) Stock Analysis: Exploring A Potential 823.91% Upside - DirectorsTalk Interviews Fri, 13 Feb 2026 08
- Cancer drug Multikine nears final U.S. trial, seeks Saudi breakthrough status - Stock Titan Mon, 29 Dec 2025 08
- Why DID CVM Shares Rally Over 7% Today? - Stocktwits Mon, 26 Jan 2026 20
- Kersten Geert buys Cel Sci (CVM) shares worth $200000 - Investing.com Mon, 26 Jan 2026 08
- $CVM stock is up 13% today. Here's what we see in our data. | CVM Stock News - Quiver Quantitative Mon, 25 Aug 2025 07
- Top Executive Makes Bold Move With Fresh Cel-Sci Stock Buy - TipRanks Mon, 26 Jan 2026 08
- CEL-SCI (CVM) Price Target Decreased by 91.67% to 25.50 - Nasdaq Wed, 04 Feb 2026 08
- CEL-SCI shares drop on proposed public offering - MSN Wed, 04 Feb 2026 02
- CEL-SCI Announces Proposed Public Offering - Business Wire Wed, 27 Aug 2025 07
- Cel-Sci Corporation (CVM) Stock Analysis: Biotechnology Innovator with 540% Potential Upside - DirectorsTalk Interviews Fri, 07 Nov 2025 08
- CEL-SCI stock falls after pricing $10M public offering at discount - Investing.com hu, 28 Aug 2025 07
- Insider Stock Purchases: January 26, 2026 | AVO Stock News - Quiver Quantitative Mon, 26 Jan 2026 08
- CEL-SCI Corp. Prices Public Offering Of 1.11 Mln Shares At $9.00/shr - Nasdaq Wed, 27 Aug 2025 07
- CEL-SCI Cancer Drug Shows 73% Survival Rate, Fast-Tracks Saudi Market Entry in 60 Days - Stock Titan Fri, 11 Jul 2025 07
- Cel-Sci Corporation (CVM) Stock Analysis: Unpacking the 3,404% Potential Upside in Biotechnology - DirectorsTalk Interviews Fri, 25 Jul 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 38023 | 200001 | — | Purchase at price 5.26 per share. | KERSTEN GEERT R | Chief Executive Officer | — | 2026-01-22 00:00:00 | D |
| 1 | 998 | 5249 | — | Stock Award(Grant) at price 5.26 per share. | KERSTEN GEERT R | Chief Executive Officer | — | 2025-12-31 00:00:00 | D |
| 2 | 815 | 4287 | — | Stock Award(Grant) at price 5.26 per share. | PRICHEP PATRICIA B | Chief Financial Officer | — | 2025-12-31 00:00:00 | D |
| 3 | 456 | 2399 | — | Stock Award(Grant) at price 5.26 per share. | TALOR EYAL | Officer | — | 2025-12-31 00:00:00 | D |
| 4 | 8389 | 49998 | — | Purchase at price 5.96 per share. | KERSTEN GEERT R | Chief Executive Officer | — | 2025-12-04 00:00:00 | D |
| 5 | 570 | 5244 | — | Stock Award(Grant) at price 9.20 per share. | KERSTEN GEERT R | Chief Executive Officer | — | 2025-09-30 00:00:00 | D |
| 6 | 466 | 4287 | — | Stock Award(Grant) at price 9.20 per share. | PRICHEP PATRICIA B | Chief Financial Officer | — | 2025-09-30 00:00:00 | D |
| 7 | 260 | 2392 | — | Stock Award(Grant) at price 9.20 per share. | TALOR EYAL | Officer | — | 2025-09-30 00:00:00 | D |
| 8 | 2919 | 19995 | — | Purchase at price 6.85 per share. | WATSON ROBERT EUGENE | Director | — | 2025-07-25 00:00:00 | D |
| 9 | 29197 | 199999 | — | Purchase at price 6.85 per share. | KERSTEN GEERT R | Chief Executive Officer | — | 2025-07-25 00:00:00 | D |
Financials
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -20.88M | -22.21M | -27.56M | -32.16M |
| TotalUnusualItems | 366.79K | 990.52K | ||
| TotalUnusualItemsExcludingGoodwill | 366.79K | 990.52K | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -25.41M | -26.92M | -32.19M | -36.70M |
| ReconciledDepreciation | 3.89M | 3.97M | 3.96M | 3.83M |
| EBITDA | -20.88M | -22.21M | -27.56M | -31.79M |
| EBIT | -24.76M | -26.17M | -31.52M | -35.62M |
| NetInterestIncome | -648.94K | -745.67K | -675.42K | -1.08M |
| InterestExpense | 648.94K | 745.67K | 675.42K | 1.08M |
| NormalizedIncome | -25.41M | -26.92M | -32.19M | -37.07M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -25.41M | -26.92M | -32.19M | -36.70M |
| TotalExpenses | 24.81M | 26.35M | 31.48M | 36.06M |
| TotalOperatingIncomeAsReported | -24.81M | -26.35M | -31.48M | -36.06M |
| DilutedAverageShares | 4.06M | 1.80M | 1.48M | 1.44M |
| BasicAverageShares | 4.06M | 1.80M | 1.48M | 1.44M |
| DilutedEPS | -6.27 | -15.31 | -21.90 | -26.10 |
| BasicEPS | -6.27 | -15.31 | -21.90 | -26.10 |
| DilutedNIAvailtoComStockholders | -25.41M | -27.58M | -32.37M | -37.63M |
| AverageDilutionEarnings | 0.00 | -1.09M | ||
| NetIncomeCommonStockholders | -25.41M | -27.58M | -32.37M | -37.63M |
| OtherunderPreferredStockDividend | 0.00 | 659.46K | 171.55K | 929.12K |
| NetIncome | -25.41M | -26.92M | -32.19M | -36.70M |
| NetIncomeIncludingNoncontrollingInterests | -25.41M | -26.92M | -32.19M | -36.70M |
| NetIncomeContinuousOperations | -25.41M | -26.92M | -32.19M | -36.70M |
| PretaxIncome | -25.41M | -26.92M | -32.19M | -36.70M |
| OtherIncomeExpense | 47.62K | 177.68K | -42.81K | 443.15K |
| OtherNonOperatingIncomeExpenses | 47.62K | 177.68K | -42.81K | 76.36K |
| GainOnSaleOfSecurity | 366.79K | 990.52K | ||
| NetNonOperatingInterestIncomeExpense | -648.94K | -745.67K | -675.42K | -1.08M |
| InterestExpenseNonOperating | 648.94K | 745.67K | 675.42K | 1.08M |
| OperatingIncome | -24.81M | -26.35M | -31.48M | -36.06M |
| OperatingExpense | 24.81M | 26.35M | 31.48M | 36.06M |
| ResearchAndDevelopment | 15.89M | 18.16M | 22.47M | 25.36M |
| SellingGeneralAndAdministration | 8.92M | 8.19M | 9.00M | 10.71M |
| GeneralAndAdministrativeExpense | 8.92M | 8.19M | 9.00M | 10.71M |
| OtherGandA | 8.92M | 8.19M | 9.00M | 10.71M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 8.02M | 2.13M | 1.58M | 1.45M |
| ShareIssued | 8.02M | 2.13M | 1.58M | 1.45M |
| TotalDebt | 9.38M | 11.62M | 13.57M | 15.30M |
| TangibleBookValue | 15.84M | 12.70M | 13.02M | 31.95M |
| InvestedCapital | 15.96M | 12.87M | 13.21M | 32.16M |
| WorkingCapital | 6.47M | 1.44M | 1.33M | 20.77M |
| NetTangibleAssets | 15.84M | 12.70M | 13.02M | 31.95M |
| CapitalLeaseObligations | 9.38M | 11.62M | 13.57M | 15.30M |
| CommonStockEquity | 15.96M | 12.87M | 13.21M | 32.16M |
| TotalCapitalization | 15.96M | 12.87M | 13.21M | 32.16M |
| TotalEquityGrossMinorityInterest | 15.96M | 12.87M | 13.21M | 32.16M |
| StockholdersEquity | 15.96M | 12.87M | 13.21M | 32.16M |
| RetainedEarnings | -539.42M | -514.01M | -487.09M | -454.90M |
| AdditionalPaidInCapital | 555.30M | 526.86M | 499.83M | 486.63M |
| CapitalStock | 80.16K | 21.27K | 474.22K | 434.48K |
| CommonStock | 80.16K | 21.27K | 474.22K | 434.48K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 12.20M | 14.12M | 17.31M | 18.36M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 7.07M | 9.51M | 11.73M | 13.70M |
| OtherNonCurrentLiabilities | 125.00K | 125.00K | 125.00K | 125.00K |
| DerivativeProductLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 6.94M | 9.38M | 11.60M | 13.57M |
| LongTermCapitalLeaseObligation | 6.94M | 9.38M | 11.60M | 13.57M |
| CurrentLiabilities | 5.13M | 4.62M | 5.59M | 4.66M |
| OtherCurrentLiabilities | 437.38K | |||
| CurrentDebtAndCapitalLeaseObligation | 2.44M | 2.24M | 1.97M | 1.73M |
| CurrentCapitalLeaseObligation | 2.44M | 2.24M | 1.97M | 1.73M |
| PayablesAndAccruedExpenses | 2.69M | 2.38M | 3.62M | 2.93M |
| CurrentAccruedExpenses | 711.82K | 566.04K | 1.05M | 842.49K |
| Payables | 1.98M | 1.81M | 2.57M | 2.09M |
| OtherPayable | 916.59K | 363.31K | 557.24K | 471.49K |
| AccountsPayable | 1.06M | 1.45M | 2.01M | 1.62M |
| TotalAssets | 28.16M | 26.99M | 30.53M | 50.52M |
| TotalNonCurrentAssets | 16.56M | 20.94M | 23.61M | 25.09M |
| OtherNonCurrentAssets | 1.22M | 1.48M | 74.67K | 164.30K |
| NonCurrentPrepaidAssets | 2.32M | 2.32M | 2.32M | 0.00 |
| GoodwillAndOtherIntangibleAssets | 119.86K | 165.49K | 197.70K | 212.20K |
| OtherIntangibleAssets | 119.86K | 165.49K | 197.70K | 212.20K |
| NetPPE | 12.90M | 16.98M | 21.02M | 24.71M |
| AccumulatedDepreciation | -12.06M | -10.07M | -7.94M | -5.85M |
| GrossPPE | 24.96M | 27.04M | 28.96M | 30.56M |
| Leases | 13.92M | 13.92M | 13.92M | 13.54M |
| OtherProperties | 10.93M | 13.01M | 14.94M | 16.92M |
| MachineryFurnitureEquipment | 104.59K | 104.59K | 99.30K | 99.30K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 11.60M | 6.06M | 6.92M | 25.44M |
| PrepaidAssets | 339.39K | 297.60K | 524.61K | 762.06K |
| Inventory | 303.28K | 1.02M | 2.25M | 2.00M |
| RawMaterials | 303.28K | 1.02M | 2.25M | 2.00M |
| Receivables | 0.00 | 54.92K | ||
| AccountsReceivable | 0.00 | 54.92K | ||
| CashCashEquivalentsAndShortTermInvestments | 10.95M | 4.74M | 4.15M | 22.67M |
| OtherShortTermInvestments | 0.00 | 6.15M | ||
| CashAndCashEquivalents | 10.95M | 4.74M | 4.15M | 22.67M |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| FreeCashFlow | -17.16M | -18.92M | -23.22M | -18.90M |
| RepaymentOfDebt | -2.36M | -2.22M | -1.56M | -1.39M |
| IssuanceOfDebt | 350.00K | 450.00K | 0.00 | 786.45K |
| IssuanceOfCapitalStock | 28.51M | 23.66M | 6.55M | 0.00 |
| CapitalExpenditure | -38.11K | -108.09K | -372.26K | -660.63K |
| InterestPaidSupplementalData | 768.47K | 923.81K | 1.06M | 1.16M |
| EndCashPosition | 10.95M | 4.74M | 4.15M | 22.67M |
| BeginningCashPosition | 4.74M | 4.15M | 22.67M | 36.06M |
| ChangesInCash | 6.22M | 592.44K | -18.53M | -13.39M |
| FinancingCashFlow | 23.37M | 19.51M | 4.69M | -638.43K |
| CashFlowFromContinuingFinancingActivities | 23.37M | 19.51M | 4.69M | -638.43K |
| NetOtherFinancingCharges | -3.13M | -2.37M | -744.91K | -169.44K |
| ProceedsFromStockOptionExercised | 0.00 | 447.29K | 131.06K | 6.73M |
| NetCommonStockIssuance | 28.51M | 23.66M | 6.55M | 0.00 |
| CommonStockIssuance | 28.51M | 23.66M | 6.55M | 0.00 |
| NetIssuancePaymentsOfDebt | -2.01M | -1.77M | -1.56M | -600.04K |
| NetShortTermDebtIssuance | 0.00 | 0.00 | 0.00 | |
| ShortTermDebtPayments | -350.00K | -450.00K | 0.00 | |
| ShortTermDebtIssuance | 350.00K | 450.00K | 0.00 | |
| NetLongTermDebtIssuance | -2.01M | -1.77M | -1.56M | -600.04K |
| LongTermDebtPayments | -2.01M | -1.77M | -1.56M | -1.39M |
| LongTermDebtIssuance | 0.00 | 786.45K | 1.61M | |
| InvestingCashFlow | -38.11K | -108.09K | -372.26K | 5.49M |
| CashFlowFromContinuingInvestingActivities | -38.11K | -108.09K | -372.26K | 5.49M |
| NetInvestmentPurchaseAndSale | 0.00 | 6.15M | -6.15M | |
| SaleOfInvestment | 0.00 | 6.15M | ||
| PurchaseOfInvestment | -6.15M | |||
| NetPPEPurchaseAndSale | -38.11K | -94.88K | -361.89K | -637.89K |
| PurchaseOfPPE | -38.11K | -94.88K | -361.89K | -637.89K |
| CapitalExpenditureReported | 0.00 | -13.21K | -10.37K | -22.74K |
| OperatingCashFlow | -17.12M | -18.81M | -22.85M | -18.24M |
| CashFlowFromContinuingOperatingActivities | -17.12M | -18.81M | -22.85M | -18.24M |
| ChangeInWorkingCapital | 1.16M | -1.21M | -1.78M | 2.48M |
| ChangeInOtherWorkingCapital | -3.58K | 745.00 | -2.32M | 1.91M |
| ChangeInOtherCurrentLiabilities | 31.44K | |||
| ChangeInPayablesAndAccruedExpense | 231.30K | -1.11M | 550.69K | 563.66K |
| ChangeInAccruedExpense | 120.73K | -458.49K | 207.09K | -16.72K |
| ChangeInPayable | 110.57K | -654.51K | 343.60K | 580.38K |
| ChangeInAccountPayable | -442.71K | -460.58K | 257.85K | 374.89K |
| ChangeInPrepaidAssets | -42.55K | 72.67K | 151.94K | 167.65K |
| ChangeInInventory | 973.66K | -172.61K | -156.73K | -159.43K |
| ChangeInReceivables | 54.92K | 0.00 | ||
| OtherNonCashItems | 345.07K | 4.87K | 15.29K | 109.39K |
| StockBasedCompensation | 2.88M | 5.35M | 7.15M | 12.38M |
| AssetImpairmentCharge | 18.27K | 0.00 | 0.00 | 30.79K |
| DepreciationAmortizationDepletion | 3.89M | 3.97M | 3.96M | 3.83M |
| DepreciationAndAmortization | 3.89M | 3.97M | 3.96M | 3.83M |
| OperatingGainsLosses | -367.41K | 713.62K | ||
| GainLossOnInvestmentSecurities | -367.41K | 713.62K | ||
| NetIncomeFromContinuingOperations | -25.41M | -26.92M | -32.19M | -36.70M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CVM
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|